CFO de­parts In­ter­cept as trick­le be­comes mass ex­o­dus from NASH biotech

5 years ago
People

Ther­mo Fish­er will drop a whop­ping $600M in­to its man­u­fac­tur­ing sup­ply chain as Covid-19 work ramps up

5 years ago
Outsourcing
Manufacturing

FDA calls out Kar­dashi­an drug pro­mo video for false claims

5 years ago
FDA+

Covid-19 roundup: US lands an­oth­er 100M-dose con­tract from J&J to back Biden's pledge; Pfiz­er and BioN­Tech could ...

5 years ago
Coronavirus

With prof­its lag­ging, Em­ma Walm­s­ley, Big Phar­ma's on­ly woman CEO, may once again be its low­est paid

5 years ago
People
Pharma

An­oth­er SPAC is gear­ing up to go pub­lic, this time com­ing from Oleg Nodel­man's EcoR1 Cap­i­tal

5 years ago
Financing

In­no­va­tion in the clin­ic is pick­ing up steam. How adap­tive de­signs could pave the road to per­son­al­ized med­i­cine

5 years ago
Biotech Voices

Eli Lil­ly tops up pos­i­tive PhI­II da­ta for its Covid-19 an­ti­body com­bo at ‘the op­ti­mal dose’

5 years ago
R&D
Coronavirus

AgomAb Ther­a­peu­tics looks to take its 'true MET ag­o­nist' for broad use in­to the clin­ic with $74M round

5 years ago
Financing

Eli Lil­ly pro­motes Edgar­do Her­nan­dez to head its man­u­fac­tur­ing op­er­a­tions as 19-year vet O'Neill hits the ex­it

5 years ago
People
Manufacturing

FDA in­spec­tion back­log tops 1,000 — and could last for years — as House hear­ing rais­es se­ri­ous con­cerns

5 years ago
FDA+
Manufacturing

Koch's 'dis­rup­tive' VC bets $110M on one of Flag­ship's new, big com­pu­ta­tion­al star­tups

5 years ago
Financing

Mer­ck inks Keytru­da deal with Sur­face On­col­o­gy; Rock­et Phar­ma­ceu­ti­cals gets ex­pe­dit­ed re­view of gene ther­a­py for rare ...

5 years ago
News Briefing

Mod­er­na finds a con­tract man­u­fac­tur­ing part­ner to scale up vac­cine sup­ply

5 years ago
R&D
Manufacturing

Chi­na's Yisheng­Bio chron­i­cles come­back sto­ry in Hong Kong IPO while plot­ting big moves in in­fec­tious dis­eases, can­cer

5 years ago
Financing
China

Saman­tha Truex's Quench Bio calls it quits af­ter fail­ing to solve the Gas­der­min D in­flam­ma­tion puz­zle

5 years ago
Pharma

No­var­tis sues FDA over its stance on Sanofi block­buster’s ex­clu­siv­i­ty

5 years ago
FDA+

Ex­clu­sive: Ready to ex­it 'qui­et mode,' joint en­ti­ty Ven­tyx de­buts its im­mune mod­u­la­tor pipeline with $114M round

5 years ago
Financing
Startups

Covid-19 roundup: Abi­vax pulls the plug on its an­ti-in­flam­ma­to­ry treat­ment; J&J says it could fall short on Q2 ...

5 years ago
Coronavirus

No more squint­ing at menus? Vi­s­us Ther­a­peu­tics nabs $36M for pres­by­opia-cor­rect­ing eye drop

5 years ago
Financing

Take­da goes all in with build-to-buy play, pick­ing up Mav­er­ick and its clin­ic-ready T cell en­gagers for $525M

5 years ago
Deals

No­var­tis' first at­tempt to repli­cate a stun­ning can­cer re­sult falls flat

5 years ago
R&D

Ex­clu­sive: For­mer In­ter­cept CMO lands new gig at Q32 Bio, two weeks af­ter leav­ing the NASH biotech

5 years ago
People

An­a­lysts picked the top 4 block­buster con­tenders in the mix — and #1 is a $3.8B coin toss

5 years ago
R&D
Pharma
First page Previous page 724725726727728729730 Next page Last page
A service from the Financial Times